Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accounts Payables (2019 - 2025)

Historic Accounts Payables for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • C4 Therapeutics' Accounts Payables fell 1136.97% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1136.97%. This contributed to the annual value of $1.3 million for FY2024, which is 816.04% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Accounts Payables is $1.3 million, which was down 1136.97% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Accounts Payables registered a high of $4.5 million during Q4 2021, and its lowest value of $683000.0 during Q1 2025.
  • For the 5-year period, C4 Therapeutics' Accounts Payables averaged around $2.3 million, with its median value being $1.6 million (2024).
  • As far as peak fluctuations go, C4 Therapeutics' Accounts Payables crashed by 7399.02% in 2022, and later skyrocketed by 14271.63% in 2025.
  • C4 Therapeutics' Accounts Payables (Quarter) stood at $4.5 million in 2021, then crashed by 73.99% to $1.2 million in 2022, then rose by 23.38% to $1.4 million in 2023, then fell by 8.16% to $1.3 million in 2024, then grew by 0.38% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $683000.0 during Q1 2025.